#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

#### FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

> September 14, 2016 Date of Report (Date of Earliest Event Reported)

#### The Chemours Company

(Exact Name of Registrant as Specified in Its Charter)

Delaware (State or Other Jurisdiction Of Incorporation) **001-36794** (Commission

File Number)

(I.R.S. Employer Identification No.)

46-4845564

1007 Market Street Wilmington, Delaware, 19899 (Address of principal executive offices)

Registrant's telephone number, including area code: (302) 773-1000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

#### Item 7.01 Regulation FD Disclosure.

On September 14, 2016, The Chemours Company (the "Company") furnished presentation slides which will be used for discussions with investors during the month of September 2016. The presentation slides are furnished herewith as Exhibit 99.1. These slides will also be made available on the Investor Relations section of the Company's website.

The presentation slides are being furnished pursuant to Item 7.01, and the information contained therein shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities under that Section. Furthermore, the information contained in Exhibit 99.1 shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act of 1933, as amended.

#### Item 9.01. Financial Statements and Exhibits

(d) Exhibits.

99.1 Investor Presentation Slides September 2016

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

THE CHEMOURS COMPANY

By: /s/ Mark E. Newman Mark E. Newman

Senior Vice President and Chief Financial Officer Date: September 14, 2016



# The Chemours Company Investor Meetings

September 2016

## Safe Harbor Statement

This presentation contains forward-looking statements, which often may be identified by their use of words like "plans," "expects," "will," "believes," "intends," "estimates," targets," "anticipates" or other words of similar meaning. These forward-looking statements address, among other things, our anticipated future operating and financial performance, business plans and prospects, transformation plans, resolution of environmental liabilities, litigation and other contingencies, plans to increase profitability, our ability to pay or the amount of any dividend, and target leverage that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements are not guarantees of future performance and are based on certain assumptions and expectations of future events which may not be realized. The matters discussed in these forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those projected, anticipated or implied in the forward-looking statements, as further described in our filings with the Securities and Exchange Commission, including our annual report on Form 10-K for the fiscal year ended December 31, 2015. Chemours undertakes no duty to update any forward-looking statements.

This presentation contains certain supplemental measures of performance that are not required by, or presented in accordance with, generally accepted accounting principles in the United States ("GAAP"). These Non-GAAP measures include Adjusted Net Income (Loss), Adjusted EPS, Adjusted EBITDA and Free Cash Flow, which should not be considered as replacements of GAAP. Free Cash Flow is defined as Cash from Operations minus cash used for PP&E purchases. Further information with respect to and reconciliations of such measures to the nearest GAAP measure can be found in the appendix hereto.


Management uses Adjusted Net Income (Loss), Adjusted EPS, Adjusted EBITDA and Free Cash Flow to evaluate the Company's performance excluding the impact of certain non-cash charges and other special items in order to have comparable financial results to analyze changes in our underlying business from quarter to quarter.

Historical results prior to July 1, 2015 are presented on a stand-alone basis from DuPont historical results and are subject to certain adjustments and assumptions as indicated in this presentation, and may not be an indicator of future performance.

Additional information for investors is available on the company's website at investors.chemours.com.




### The Chemours Company at a Glance



# **Transformation Plan Priorities**

<ul> <li>Targeting additional cost reduction of \$150M in 2017</li> <li>Optimize The Portfolio</li> <li>Completed strategic review of Chemical Solutions segment</li> <li>Closed Aniline, Sulfur and Clean &amp; Disinfect sales, generated ~\$695M in gross proceeds</li> <li>Retaining and improving cost position of Belle, WV site</li> <li>Support customer growth in TiO<sub>2</sub> through successful Altamira start-up and disciplined approach</li> <li>Continue ramp up of Opteon™ product lines in Fluoroproducts</li> <li>Grow Cyanides business with key customers</li> <li>Target \$150M Adjusted EBITDA growth from Opteon™ and Altamira through 2017</li> <li>Concentrate capital spending on investable business portfolio</li> <li>Announced investment in the next increment of Opteon™ capacity</li> <li>Rationalize annual capital spending to ~\$350M over time</li> <li>Foster an entrepreneurial organization</li> <li>Operate with a simpler structure</li> <li>Maintain a commitment to a safe and sustainable future</li> </ul>	
Optimize The Portfolio       • Closed Aniline, Sulfur and Clean & Disinfect sales, generated ~\$695M in gross proceeds         • Retaining and improving cost position of Belle, WV site       • Support customer growth in TiO₂ through successful Altamira start-up and disciplined approach         • Continue ramp up of Opteon ™ product lines in Fluoroproducts       • Continue ramp up of Opteon ™ product lines in Fluoroproducts         • Grow Cyanides business with key customers       • Target \$150M Adjusted EBITDA growth from Opteon ™ and Altamira through 2017         Refocus Investments       • Concentrate capital spending on investable business portfolio         • Announced investment in the next increment of Opteon ™ capacity       • Rationalize annual capital spending to ~\$350M over time         • Foster an entrepreneurial organization       • Operate with a simpler structure	
Portfolio       • Closed Anline, Sulfur and Clean & Disinfect sales, generated ~\$695M in gross proceeds         • Retaining and improving cost position of Belle, WV site         • Support customer growth in TiO₂ through successful Altamira start-up and disciplined approach         • Continue ramp up of Opteon™ product lines in Fluoroproducts         • Concentrate ramp up of Opteon™ product lines in Fluoroproducts         • Target \$150M Adjusted EBITDA growth from Opteon™ and Altamira through 2017         • Concentrate capital spending on investable business portfolio         • Announced investment in the next increment of Opteon™ capacity         • Rationalize annual capital spending to ~\$350M over time         • Foster an entrepreneurial organization         • Operate with a simpler structure	
<ul> <li>Retaining and improving cost position of Belle, WV site</li> <li>Support customer growth in TiO₂ through successful Altamira start-up and disciplined approach</li> <li>Continue ramp up of Opteon™ product lines in Fluoroproducts</li> <li>Grow Cyanides business with key customers</li> <li>Target \$150M Adjusted EBITDA growth from Opteon™ and Altamira through 2017</li> <li>Concentrate capital spending on investable business portfolio</li> <li>Announced investment in the next increment of Opteon™ capacity</li> <li>Rationalize annual capital spending to ~\$350M over time</li> <li>Foster an entrepreneurial organization</li> <li>Operate with a simpler structure</li> </ul>	
Grow Market Positions       • Continue ramp up of Opteon™ product lines in Fluoroproducts         • Grow Cyanides business with key customers       • Grow Cyanides business with key customers         • Target \$150M Adjusted EBITDA growth from Opteon™ and Altamira through 2017         • Concentrate capital spending on investable business portfolio         • Announced investment in the next increment of Opteon™ capacity         • Rationalize annual capital spending to ~\$350M over time         • Foster an entrepreneurial organization         • Operate with a simpler structure	
Positions       • Grow Cyanides business with key customers • Target \$150M Adjusted EBITDA growth from Opteon ™ and Altamira through 2017         Refocus Investments       • Concentrate capital spending on investable business portfolio • Announced investment in the next increment of Opteon ™ capacity 	ach to prici
<ul> <li>Target \$150M Adjusted EBITDA growth from Opteon ™ and Altamira through 2017</li> <li>Concentrate capital spending on investable business portfolio</li> <li>Announced investment in the next increment of Opteon ™ capacity</li> <li>Rationalize annual capital spending to ~\$350M over time</li> <li>Foster an entrepreneurial organization</li> <li>Operate with a simpler structure</li> </ul>	
Refocus Investments       • Concentrate capital spending on investable business portfolio         • Announced investment in the next increment of Opteon ™ capacity         • Rationalize annual capital spending to ~\$350M over time         • Foster an entrepreneurial organization         • Operate with a simpler structure	
Refocus Investments       • Announced investment in the next increment of Opteon ™ capacity         • Rationalize annual capital spending to ~\$350M over time         • Foster an entrepreneurial organization         • Operate with a simpler structure	
<ul> <li>Announced investment in the next increment of Opteon M capacity</li> <li>Rationalize annual capital spending to ~\$350M over time</li> <li>Foster an entrepreneurial organization</li> <li>Operate with a simpler structure</li> </ul>	
<ul> <li>Rationalize annual capital spending to ~\$350M over time</li> <li>Foster an entrepreneurial organization</li> <li>Operate with a simpler structure</li> </ul>	
Operate with a simpler structure	
Operate with a simpler structure	
Maintain a commitment to a safe and sustainable future	
Plan Well Underway to Enhance Adjusted EBITDA by \$500M, Improve Free Cash Flow and Reduce Leverage to ~3x in 2017	

## A Year of Transformation







# **Titanium Technologies**


# **Chemours Titanium Technologies Business Overview**

#### **Business Overview**

- Global leader in TiO<sub>2</sub> with production capacity of 1.25 million metric tons(1)
  - 4 TiO<sub>2</sub> plants with 7 production lines<sup>(1)</sup> -
  - Packaging facility at Kallo, Belgium -
  - Mineral sands mine at Starke, FL -
- Industry-leading manufacturing cost position
  - Unique chloride technology
  - Feedstock flexibility
- Strong brand reputation


**Chemours**<sup>®</sup>

Ti-Pure<sup>™</sup> sold to ~800 customers globally



Source: Company filings and data. Titanium Technologies: TZMI (2015) (1) Pro forma for completion of Altamira expansion (2) TiO<sub>2</sub> market share statistics based on volume statistics from company filings and market estimates (3) Reflects full year 2015 segment net sales

Chemours is #1 in TiO<sub>2</sub> Globally<sup>(2)</sup>




- Coatings architectural, industrial, . automotive
- Plastics rigid / flexible packaging, PVC pipe/windows
- Papers laminate papers, coated . paper/paperboard, sheet
- Specialty rubber, leather, diesel . particulate filters

6

# **TiO<sub>2</sub> Process Technologies & Chemours Capabilities**

Chemours has scale, leading process technology and manufacturing flexibility creating a sustainable low-cost position adaptable to customer needs and market conditions

# **TiO2 Process Technologies**




## **The Chemours Advantage**

- 100% chloride process
- Highest throughput operations
- Process technology and operational discipline
- Flexible manufacturing circuit with sustainable expansion options



# TiO<sub>2</sub> Market Segments Addressed by Producers

# Chemours delivers high-quality product to serve customers in attractive higher value-add segments of the TiO<sub>2</sub> market




- Quality and performance of TiO<sub>2</sub> products differ considerably across market segments and applications
- Segments are supplied by two manufacturing systems (Regional and Multinational Producers)
- Utilization is higher at manufacturing facilities supplying specialty and higher value pigment segments
- Separation remains in multipurpose segments based on pigment quality, product design and supply capability

Source: Chemours Estimates



# **TiO<sub>2</sub> Market: Cost Differentials**

Chemours' product value and cost offer supply security in a stressed  $\mathrm{TiO}_2$  industry



# Chemours' Profitability Focus in TiO<sub>2</sub>

# Working towards improving profitability that supports sustainable reinvestment levels

#### Pricing Actions

- January 1 price increase implemented across the globe
- May 1 increase implemented across the globe
- Announced September 1 price increase of \$150/t in EMEA and Latin America
- Chemours applies an analytical approach to pricing and will seek prices consistent with factors such as:
  - Product value
  - Supply/Demand
  - Reinvestment economics

#### **Cost Reductions**

- Shutdown of Edge Moor plant and line at New Johnsonville, TN
- Integrated ore capability from sourcing to use
- Fixed cost and working capital reductions as part of Transformation Plan






# Fluoroproducts


### Fluoroproducts Business Overview

#### **Business Overview**

- Supplies products for high performance applications across broad array of industries
- #1 in Fluoroproducts globally
  - Fluorochemicals: #1 in refrigerants, #1 in propellants, #3 in foaming agents
  - Fluoropolymers: #1 in industrial resins, #1 in fluoropolymer specialties
- Key Brands include Teflon<sup>™</sup>, Freon<sup>™</sup>, Opteon<sup>™</sup> Krytox <sup>™</sup>, Nafion<sup>™</sup>, Viton<sup>™</sup>

#### Chemours is #1 in Fluoroproducts Globally<sup>(2)</sup>





 Fluorochemicals – mainly refrigerants, propellants, and foam expansion agent


- Fluoropolymers mainly industrial resins and downstream products & coatings
- Key End Markets AC, refrigeration, automotive, aerospace, wire & cable, consumer electronics and telecommunications

Source: Company filings and data, Fluoroproducts: Company filings and Management estimates (1) Reflects full year 2015 segment net sales (2) Fluorochemicals and fluoropolymers market share statistics based on 2015 internal revenue estimates and company filings (3) Includes 100% contribution from the DuPont-Mitsui Fluorocarbon Company joint venture Chemours<sup>--</sup>



### Fast Pace Adoption of Opteon™

#### Opteon<sup>™</sup> Technology offers sustainable technology option in the face of upcoming regulatory deadlines



## Fluoropolymers: Tailored Solutions for Growth Opportunities

# Chemours delivers high value fluoropolymer solutions used in complex and highly demanding applications

#### Market Dynamics

- Demand conditions driven by GDP growth in North America Europe and slower growth in China
- Weak Euro and Yen in 2015 led to pricing pressures
- Chemours' strong collaborations in automotive, telecommunications, and consumer electronics markets provide solid base of demand and growth opportunities
- Targeted innovation and application development in fluoropolymer resins and formulations expected to produce future customer solutions



### **Diverse End-Use Applications**



Consumer Electronics – Teflon™ Faster data speeds & power/data combination cable designs



Energy Storage – Nafion<sup>™</sup> Specialty ion exchange polymer membrane to store alternative energy in flow batteries

#### Turbo Charger Hoses – Viton™

Enable higher engine temperatures and advanced technology options to drive fuel efficiency improvements






# Chemical Solutions

# Strategic Review of Chemical Solutions Portfolio Complete

Strategic Review Results										
Divest										
AnilineSulfurClean & Disinfect• Sold to Dow for ~\$140 million• Sold to Veolia for \$325 million• Sold to Lanxess for \$230 millio• Completed March 2016• Completed July 2016• Completed September 2016Total gross proceeds of ~\$695 million - Average multiple of ~10 – 12xMinimal net free cash flow impactFocus to drive out stranded costs as part of Five-Point Transformation Plan										
Close			Reta	ain						
Reactive Metals <ul> <li>Expected end of 2016</li> </ul>	5	Cyanid	les	Belle, WV Site*						
Includes Methylamines, Glycolic and Vazo p	product lines									
Chemours <sup>-</sup>										

## **Chemours Cyanide Opportunity**



#### **Americas Sodium Cyanide Market**

#### Americas NaCN demand forecast to grow at 9% CAGR over next four years

- Remains net import market
- Deteriorating ore quality contributes to underlying NaCN demand growth



Source: Chemours internal estimates

#### **The Chemours Advantage**

- Aligned with customer values
- On-purpose producer, reliable supply
- Differentiating product stewardship
- Strong logistics network
- Long term contracts



# Financial Position

Chemours<sup>-</sup>


(\$ in millions unless otherwise noted)

## **Second Quarter Financial Summary**

	2Q16	2Q15	$\overset{\Delta}{\mathbf{Yr}/\mathbf{Yr}}$	1Q16	$\Delta$ Seq.	
Net Sales	\$1,383	\$1,508	(\$125)	\$1,297	\$86	Year-over-year <ul> <li>Transformation Plan cost</li> </ul>
Adj. EBITDA	187	127	\$60	128	\$59	reductions and Opteon™ growth were partially offset by lower
Adj. EBITDA Margin (%)	13.5	8.4	5.1	9.9	3.6	$TiO_2$ pricing and currency headwinds
Net Income (loss)	(18)	(18)	0	51	(69)	<ul> <li>Continued meaningful improvement in Free Cash Flow</li> </ul>
Adj. Net Income	49	17	32	11	38	performance
EPS <sup>1</sup>	(\$0.10)	(\$0.10)	\$0	\$0.28	(\$0.38)	<ul> <li><u>Sequentially</u></li> <li>Benefits from seasonal TiO<sub>2</sub> and</li> </ul>
Adj. EPS <sup>1</sup>	\$0.27	\$0.09	\$0.18	\$0.06	\$0.21	refrigerant volumes, higher TiO <sub>2</sub> pricing, cost reductions and
Free Cash Flow <sup>2</sup>	\$11	(\$145)	\$156	(\$219)	\$230	Opteon™ growth led to improved profitability

See reconciliation of non-GAAP measures in the Appendix <sup>1</sup> Periods prior to 3Q15 are represented by pro forma diluted EPS <sup>2</sup> Defined as Cash from Operations minus cash used for PP&E purchases; 1Q16 excludes benefit from DuPont prepayment of ~\$166M as at 3/31/16

# Liquidity Profile Since Spin



2016 Adjusted EBITDA Expected to be Greater than 2015, including \$200M of Transformation Savings, Generating Modestly Positive Free Cash Flow

#### Key Factors Influencing 2016 Performance:

#### Market Factors

- TiO<sub>2</sub> price
- Currency
- End-market demand

#### **Chemours Initiatives**

- Cost reductions
- Working capital productivity
- Ramp up in Opteon<sup>™</sup>
- Altamira start-up





# Appendix

# **TiO<sub>2</sub> Applications**

# Quality and performance of TiO<sub>2</sub> products differ considerably across segments of the market that serve different applications

Specialty and High Quality Applications: 40%	
<ul> <li>Performance polymers, Exterior Architectural Paint, Automated Tint System Coatings and durable Industrial coatings</li> </ul>	
<ul> <li>Commands premium due to superior pigment product design &amp; performance</li> </ul>	
<ul> <li>Pharma, Food and Cosmetics*</li> </ul>	
Multi-Purpose Applications: 30%	
<ul> <li>High quality architectural paint, white, industrial coatings</li> </ul>	
<ul> <li>Commands premium due to interior/exterior durability and a high level of product consistency</li> </ul>	
Fit for Use Applications: 20%	
<ul> <li>Interior arch factory color paint, fibers, non durable polymer applications</li> </ul>	
<ul> <li>Less stringent batch to batch variability requirements (lesser pigment quality needs)</li> </ul>	
<ul> <li>Lowest Quality requirement Applications: 10%</li> </ul>	
Ceramics, road paint     Chemours does not participate in these applications	
Chemours"	23

## Segment Net Sales and Adjusted EBITDA (unaudited)

#### SEGMENT NET SALES (UNAUDITED)

(\$ in millions unless otherwise noted)	LTM									
		2Q16 20		2Q16		1Q16	4Q15		1	3Q15
Titanium Technologies	\$	2,322	\$	596	\$	521	\$	589	\$	616
Fluoroproducts		2,194		573		531		515		575
Chemical Solutions	<u></u>	1,010		214		245		256		295
TOTAL NET SALES	\$	5,526	\$	1,383	\$	1,297	\$	1,360	\$	1,486

#### SEGMENT ADJUSTED EBITDA (UNAUDITED)

	L	TM								
	2	Q16	2	Q16	1	Q16	4	Q15	3	Q15
Titanium Technologies	\$	307	\$	111	\$	54	\$	62	\$	80
Fluoroproducts		361		105		85		80		91
Chemical Solutions		45		11		10		16		8
Corporate & Other		(97)		(40)		(21)		(26)		(10)
TOTAL ADJUSTED EBITDA	\$	616	\$	187	\$	128	\$	132	\$	169

#### SEGMENT ADJUSTED EBITDA MARGIN (UNAUDITED)

	LTM				
	2Q16	2Q16	1Q16	4Q15	3Q15
Titanium Technologies	13.2%	18.6%	10.4%	10.5%	13.0%
Fluoroproducts	16.5%	18.3%	16.0%	15.5%	15.8%
Chemical Solutions	4.5%	5.1%	4.1%	6.3%	2.7%
Corporate & Other	0.0%	0.0%	0.0%	0.0%	0.0%
TOTAL CHEMOURS	11.1%	13.5%	9.9%	9.7%	11.4%



\* - Note summation of individual quarters may not sum to LTM figure due to rounding.

# GAAP Net Income (Loss) to Adjusted EBITDA and Adjusted Net Income Reconciliations

(\$ in millions unless otherwise noted)	otherwise noted) LTN 2Q1		2Q16		1Q16		4Q15		3	Q15
Net income (loss) attributable to Chemours	\$	(82)	\$	(18)	\$	51	\$	(86)	\$	(29)
Non-operating pension and other postretirement employee benefit costs		(32)		(7)		(7)		(8)		(10)
Exchange losses (gains)		4		14		6		28		(44)
Restructuring charges		250		9		17		85		139
Asset related charges		136		63				3		70
(Gain) loss on sale of assets or business		(79)		1		(89)		9		-
Transaction costs		24		12		3		9		-
Legal and other charges		26		13		5		8		-
Provision for (benefit from) income taxes relating to reconciling items $^1$		(116)		(38)		25		(43)		(60)
Adjusted Net Income	\$	131	\$	49	\$	11	\$	5	\$	66
Net income attributable to noncontrolling interests		-		-		-		-		-
Interest expense, net		211		50		57		53		51
Depreciation and amortization		275		73		66		66		70
All remaining (benefit from) provision for income taxes <sup>1</sup>		(1)		15		(6)		8		(18)
Adjusted EBITDA	\$	616	\$	187	\$	128	\$	132	\$	169
Adjusted earnings per share, basic <sup>2</sup>	\$	0.72	\$	0.27	\$	0.06	\$	0.03	\$	0.36
Adjusted earnings per share, diluted <sup>2</sup>	\$	0.72	\$	0.27	\$	0.06	\$	0.03	\$	0.36

<sup>1</sup> Total of provision for (benefit from) income taxes reconciles to the amount reported in the interim consolidated statement of operations for the three months ended June 30, 2016, March 31, 2016, September 31, 2015, June 30, 2015, March 31, 2015 and year ended December 31, 2015.

<sup>2</sup> On July 1, 2015, E.I. du Pont de Nemours and Company distributed 180,966,833 shares of Chemours' common stock to holders of its common stock. Basic and diluted earnings per common share for the three months ended March 31, 2015 and June 30, 2015 were calculated using the number of shares



## **Free Cash Flow Reconciliation**

(\$ in millions unless otherwise noted)	LTM 2Q16			1Q16		4Q15		3Q15	
Cash provided by (used for) operating activities Purchases of property, plant and equipment	\$ 541 (400)	\$	90 (79)	\$	36 (89)	\$	302 (127)	\$	113 (105)
FREE CASH FLOW <sup>3</sup>	\$ 141	\$	11	\$	(53)	\$	175	\$	8

<sup>3</sup> As of June 30, 2016 and March 31, 2016, remaining DuPont prepayment was ~\$131M and ~\$166M, respectively. Free Cash Flow excluding the DuPont prepayment was (\$173M) and (\$219M) for the six months ended June 30, 2016 and three months ended March 31, 2016, respectively.





©2016 The Chemours Company. Chemours™ and the Chemours Logo are trademarks or registered trademarks of The Chemours Company